米热阿依·阿力木,林大卫,潘文志

• 1:复旦大学附属中山医院心内科上海市心血管病研究所国家放射与治疗临床医学研究中心

摘要(Abstract)：

在我国，主动脉瓣反流（AR）临床检出率高，若持续进展易引发心力衰竭、心律失常等严重并发症，导致死亡率显著上升，进而给医疗体系带来沉重负担。经导管主动脉瓣置换术（TAVR）作为AR介入治疗的研究热点与核心手段，因微创，无需体外循环和术后恢复迅速等显著优势备受关注，然而，在实际应用中，TAVR也面临着如AR患者瓣膜缺乏钙化锚定等诸多挑战。本文旨在系统梳理AR介入治疗最新进展，为临床实践提供参考，内容涵盖以下几个方面：（1）适应证临床证据的更新，包括现行指南中的相关推荐、干预阈值的前移趋势、评估体系向多维化拓展以及终末期患者干预策略的突破；（2）标签外瓣膜临床研究的最新进展，涉及自膨胀式瓣膜与球囊扩张式瓣膜的性能比较、在不同瓣环周长条件下的应用情况以及针对特殊解剖结构的治疗探索；（3）标签外瓣膜领域积累的新技术，如无冠窦支点技术和“三明治”瓣中瓣置入术的应用；（4）专用TAVR瓣膜的研发进展及其优势。

关键词(KeyWords)： 主动脉瓣反流;经导管主动脉瓣置换术;适应证;临床进展

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(82270377)

作者(Author): 米热阿依·阿力木,林大卫,潘文志

参考文献(References)：

• [1] Otto CM,Nishimura RA,Bonow RO,et al.2020 ACC/AHA Guideline for the management of patients with ValvulARHeart disease:executive summary:a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation,2021,143(5):e35-e71.DOI:10.1161/CIR.0000000000000932.
• [2]Praz F,Borger MA,Lanz J,et al.2025 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2025,46(44):4635-4736.DOI:10.1093/eurheartj/ehaf194.
• [3]Pan W,Zhou D,Cheng L,et al.Aortic regurgitation is more prevalent than aortic stenosis in Chinese elderly population:implications for transcatheter aortic valve replacement[J].Int J Cardiol,2015,201:547-548.DOI:10.1016/j.ijcard.2014.10.069.
• [4] Leon MB,Smith CR,Mack MJ,et al.Transcatheter or surgical aortic-valve replacement in intermediate-risk patients[J].N Engl J Med,2016,374(17):1609-1620.DOI:10.1056/NEJMoa1514616.
• [5] Yoon SH,Schmidt T,Bleiziffer S,et al.Transcatheter aortic valve replacement in pure native aortic valve regurgitation[J].J Am Coll Cardiol,2017,70(22):2752-2763.DOI:10.1016/Macc.2017.10.006.
• [6]徐冰晨,金健好,陈莎莎,等.采用自膨胀瓣膜行经股动脉主动脉瓣置换术的全流程管理[J].介入放射学杂志,2025,34(3):311-315.DOI:10.3969/j.issn.1008-794X.2025.03.016.
• [7]Vahanian A,Beyersdorf F,Praz F,et al.2021 ESC/EACTS Guidelines for the management of valvular heart disease[J].Eur Heart J,2022,43(7):561-632.DOI:10.1093/eurheartj/ehab395.
• [8]Yang LT,Michelena HI,Scott CG,et al.Outcomes in chronic hemodynamically significant aortic regurgitation and limitations of current guidelines[J].J Am Coll Cardiol,2019,73(14):1741-1752.DOI:10.1016/j.jacc.2019.01.024.
• [9]Anand V,Michelena HI,Scott CG,et al.Echocardiographicmarkers of early left ventricular dysfunction in asymptomatic aortic regurgitation:is it time to change the guidelines?[J].JACC Cardiovasc Imaging,2025,18(3):266-274.DOI:10.1016/j.jcmg.2024.09.005.
• [10] Amoroso NS,Sharma RP,Généreux P,et al.Clinical journey for patients with aortic regurgitation:a retrospective observational study from a multicenter database[J].Catheter Cardiovasc Interv,2024,104(1):145-154.DOI:10.1002/ccd.31085.
• [11]Zhang MK,Li LN,Xue H,et al.Left ventricle reverse remodeling in chronic aortic regurgitation patients with dilated ventricle after aortic valve replacement[J].J Cardiothorac Surg,2022,17(1):8.DOI:10.1186/s13019-022-01754-5.
• [12]Anand V,Yang L,Luis SA,et al.Association of left ventricular volume in predicting clinical outcomes in patients with aortic regurgitation[J].J Am Soc Echocardiogr,2021,34(4):352-359.DOI:10.1016/j.echo.2020.11.014.
• [13]Yang LT,Lee CC,Su CH,et al.Analysis of left ventricular indexes and mortality among Asian adults with hemodynamically significant chronic aortic regurgitation[J].JAMA Netw Open,2023,6(3):e234632.DOI:10.1001/jamanetworkopen.2023.4632.
• [14] Akintoye E,Saijo Y,Braghieri L,et al.Impact of age and sex on left ventricular remodeling in patients with aortic regurgitation[J].J Am Coll Cardiol,2023,81(15):1474-1487.DOI:10.1016/j.jacc.2023.02.037.
• [15]Barradas-Pires A,Merás P,Constantine A,et al.Repair of aortic regurgitation in young adults:sooner rather than later[J].J Am Heart Assoc,2023,12(18):e029251.DOI:10.1161/JAHA.122.02925 1.
• [16]Marigliano AN,Ortiz JT,Casas J,et al.Aortic regurgitation:from valvular to myocardial dysfunction[J].J Clin Med,2024,13(10):2929.DOI:10.3390/jcm13102929.
• [17]Kammerlander AA,Wiesinger M,Duca F,et al.Diagnostic and prognostic utility of cardiac magnetic resonance imaging in aortic regurgitation[J].JACC Cardiovasc imaging,2019,12(8 Pt 1):1474-1483.DOI:10.1016/j.jcmg.2018.08.036.
• [18]Yang LT,Takeuchi M,Scott CG,et al.Automated global longitudinal strain exhibits a robust association with death in asymptomatic chronic aortic regurgitation[J].J Am Soc Echocardiogr,2022,35(7):692-702.e8.DOI:10.1016/j.echo.2021.10.018.
• [19]Fiedler AG,Bhambhani V,Laikhter E,et al.Aortic valve replacement associated with survival in severe regurgitation and low ejection fraction[J].Heart,2018,104(10):835-840.DOI:10.1136/heartjnl-2017-312024.
• [20] Gondi KT,Tam MC,Chetcuti SJ,et al.Transcatheter aortic valve replacement for left ventricular assist device-related aortic regurgitation:the Michigan medicine experience[J].J Soc Cardiovasc Angiogr Interv,2022,2(1):100530.DOI:10.1016/j.jscai.2022.100530.
• [21]Mentias A,Saad M,Menon V,et al.Transcatheter vs surgical aortic valve replacement in pure native aortic regurgitation[J].Ann Thorac Surg,2023,115(4):870-876.DOI:10.1016/j.athoracsur.2022.09.016.
• [22]Oettinger V,Hilgendorf I,Wolf D,et al.Treatment of pure aortic regurgitation using surgical or transcatheter aortic valve replacement between 2018 and 2020 in Germany[J].Front Cardiovasc Med,2023,10:1091983.DOI:10.3389/fcvm.2023.1091983.
• [23]Jha M,Agrawal SP,Maheta D,et al.Effectiveness of transcatheter aortic valve replacement in pure severe native aortic valve regurgitation:a systematic review and meta-analysis[J].Cardiol Rev,2025.DOI:10.1097/CRD.0000000000000960.
• [24]Da-Wei L,Zi-Long W,Yan-Xing F,et al.Short-term outcomes of transcatheter aortic valve replacement in low-risk patients with pure severe aortic regurgitation[J].Am J Cardiol,2024,222:58-64.DOI:10.1016/j.amjcard.2024.04.056.
• [25] Zhang J,Kong XQ,Gao XF,et al.Transfemoral transcatheter aortic valve replacement with VitaFlow~(TM)valve for pure native aortic regurgitation in patients with high surgical risk:rationale and design of a prospective,multicenter,and randomized SEASON-AR trial[J].Am Heart J,2024,271:76-83.DOI:10.1016/j.ahj.2024.02.022.
• [26]中国医师协会心血管内科医师分会结构性心脏病学组.单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J].中国介入心脏病学杂志,2023,31(11):801-809.DOI:10.3969/j.issn.1004-8812.2023.11.001.
• [27]中国医师协会心血管内科医师分会结构性心脏病学组,亚太结构性心脏病俱乐部.中国经导管主动脉瓣置换术临床路径专家共识(2024版)[J].中国介入心脏病学杂志,2024,32(11):601-617.DOI:10.3969/j.issn.1004-8812.2024.11.001.
• [28]Sanchez-Luna JP,Martin P,Dager AE,et al.Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation[J].EuroIntervention,2023,19(7):580-588.DOI:10.4244/EIJ-D-23-0034.
• [29]Yao J,Wu D,Yan Y,et al.Redefining TAVR valve sizing:a validated multiplanar approach for both bicuspid and tricuspid valves[J].JACC Cardiovasc Interv,2025,18(14):1748-1757.DOI:10.1016/j.jcin.2025.05.043.
• [30]洪楠超,陈莎莎,张源,等.经股动脉入路经导管主动脉瓣置换术治疗不同瓣环周长单纯主动脉瓣反流患者的短期预后比较[J].中国介入心脏病学杂志,2024,32(5):244-249.DOI:10.3969/j.issn.1004-8812.2024.05.002.
• [31]Yu FC,Peng XP,Yao J,et al.Transcatheter aortic valve implantation in pure aortic regurgitation:one-year outcomes of the AURORA trial[J].EuroIntervention,2025,21(16):952-960.DOI:10.4244/EIJ-D-25-00224.
• [32]Poletti E,De Backer O,Scotti A,et al.Transcatheter aortic valve replacement for pure native aortic valve regurgitation:the PANTHEON international project[J].JACC Cardiovasc Interv,2023,16(16):1974-1985.DOI:10.1016/j.jcin.2023.07.026.
• [33]Bhaskaran J,Amat Santos IJ,Manzil AS,et al.Transcatheter aortic valve replacement in pure native valve aortic regurgitation using a 35-mm balloon-expandable Myval XXL valve and a24-French Python BZ Smart introducer sheath[J].Catheter Cardiovasc Interv,2025,106(2):863-868.DOI:10.1002/ccd.31632.
• [34]Zhong W,Pan W,Liu Z,et al.Plus anchor valve replacement for treatment of severe aortic regurgitation with an extremely large annulus[J].JACC Cardiovasc Interv,2025,18(6):808-810.DOI:10.1016/j.jcin.2024.11.030.
• [35]Baumbach A,Patel KP,Rudolph TK,et al.Aortic regurgitation:from mechanisms to management[J].Euro Intervention,2024,20(17):e1062-e1075.DOI:10.4244/EIJ-D-23-00840.
• [36]Yang L,Chen S,Zhang X,et al.Comparisons of noncoronary sinus pivot implantation(NCPI)and conventional method for transcatheter aortic valve replacement with self-expanding valvein pure aortic regurgitation(PAR)[J].Catheter Cardiovasc Interv,2024,103(7):1093-1100.DOI:10.1002/ccd.31064.
• [37]Yang L,Weng Z,Chen S,et al.Noncoronary sinus pivot implantation for transcatheter aortic valve replacement with self-expanding valve for aortic regurgitation[J].JACC Asia,2025,5(7):884-894.DOI:10.1016/j.jacasi.2025.04.004.
• [38] Pan W,Lin D,Chen S,et al.Transcatheter"Sandwich"valvein-valve implantation technique for pure aortic regurgitation:operation skills and early experience[J].CVIA,2024,9(1):294-300.DOI:10.15212/cvia.2024.0007.
• [39]罗一纯,刘路路,石峻,等.应用J-Valve瓣膜经导管主动脉瓣置换术治疗高危单纯主动脉瓣反流多中心研究早期临床结果[J].中国胸心血管外科临床杂志,2019,26(8):737-743.DOI:10.7507/1007-4848.201905004.
• [40] Vahl TP,Thourani VH,Makkar RR,et al.Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation(ALIGN-AR):a prospective,multicentre,single-arm study[J].Lancet,2024,403(10435):1451-1459.DOI:10.1016/S0140-6736(23)02806-4.
• [41]Makkar RR.TAVR with Jena Valve for symptomatic aortic regurgitation in high surgical risk patients:outcomes in 500patients from the ALIGN AR trial[C].American College of Cardiology Annual Scientific Session(ACC.25),Chicago,USA,2025.
• [42]Song GY.From ALIGN-AR to ALTER-AR:one-year follow-up of TaurusTrio heart valve system for severe aortic regurgitation[C].European Course on Percutaneous Coronary Interventions(EuroPCR)2025,Paris,France,2025.
• [43]Pan W,Chen S,Li W,et al.Early results of multicenter trial of a novel balloon-expandable valve with anchor for aortic regurgitation[J].JACC Cardiovasc Interv,2025,18(6):752-764.DOI:10.1016/j.jcin.2024.12.006.
• [44] Garcia S,Ye J,Webb J,et al.Transcatheter treatment of native aortic valve regurgitation:the North American experience with a novel device[J].JACC Cardiovasc Interv,2023,16(16):1953-1960.DOI:10.1016/j.jcin.2023.05.018.
• [45]Wei L.One-year clinical follow-up results of the J-VALVE TF transvascular aortic valve system in the treatment of aortic regurgitation[C].European Course on Percutaneous Coronary Interventions(EuroPCR)2025,Paris,France,2025.
• [46] Laguna Tech.Transcatheter Aortic Valve Replacement(TAVR)for non-calcified aortic regurgitation and calcified aortic steno sis:early feasibility study results[C].Cardiovascular Research Technologies(CRT 2024)Conference,Washington,USA,2024.
• [47]Poletti E,Adam M,Wienemann H,et al.Performance of purpose-built vs.off-label transcatheter devices for aortic regurgitation:the PURPOSE study[J].JACC Cardiovasc Interv,2024,17(13):1597-1606.DOI:10.1016/j.jcin.2024.05.019.
• [48]Samimi S,Hatab T,Kharsa C,et al.Meta-analysis of dedicated vs.off-label transcatheter devices for native aortic regurgitation[J].JACC Cardiovasc Interv,2025,8(1):44-57.DOI:10.1016/j.jcin.2024.08.042.
• [49]陆蕾,潘文志.聚合物瓣膜的发展历史及研究进展[J].中国介入心脏病学杂志,2025,33(9):523-531.DOI:10.3969/j.issn.1004-8812.2025.09.006.